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BACKGROUND
Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic 
cardiovascular events. We sought to determine whether alirocumab, a human monoclonal 
antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardio-
vascular outcomes after an acute coronary syndrome in patients receiving high-intensity 
statin therapy.
METHODS
We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 
18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density 
lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non−high-
density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an 
apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a 
high-intensity dose or at the maximum tolerated dose. Patients were randomly assigned to re-
ceive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 
patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to 
target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The 
primary end point was a composite of death from coronary heart disease, nonfatal myocardial 
infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.
RESULTS
The median duration of follow-up was 2.8 years. A composite primary end-point event oc-
curred in 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the 
placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P<0.001). A total 
of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group 
died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98). The absolute benefit of alirocumab with respect 
to the composite primary end point was greater among patients who had a baseline LDL 
cholesterol level of 100 mg or more per deciliter than among patients who had a lower base-
line level. The incidence of adverse events was similar in the two groups, with the exception 
of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group).
CONCLUSIONS
Among patients who had a previous acute coronary syndrome and who were receiving high-
intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among 
those who received alirocumab than among those who received placebo. (Funded by Sanofi and 
Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402.)
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Despite the availability of current evidence-based treatments, patients who have had an acute coronary syndrome 
remain at high risk for recurrent ischemic car-
diovascular events.1,2 This residual risk is attrib-
utable in part to elevated levels of low-density 
lipoprotein (LDL) cholesterol and other athero-
genic lipoproteins. Previous clinical trials have 
shown that the risk is lower among patients who 
receive statin therapy to lower the LDL choles-
terol level than among those who receive place-
bo,3 among patients who receive high-intensity 
statins than among those who receive moderate-
intensity statins,4 and among patients who receive 
ezetimibe added to statin therapy than among 
those who receive a statin alone.5
Proprotein convertase subtilisin–kexin type 9 
(PCSK9) promotes degradation of LDL receptors, 
thereby diminishing the clearance of LDL from 
the circulation.6 Studies have shown that muta-
tions conveying gain or loss of function of PCSK9 
result in a higher or lower level of LDL choles-
terol, respectively, which in turn is associated 
with a corresponding higher7 or lower6 risk of 
incident coronary heart disease. These findings 
have led to the development of monoclonal anti-
bodies to PCSK9 that produce substantial reduc-
tions in LDL cholesterol when administered alone 
or with a statin.8-12 Two of these agents were 
reported to reduce the risk of ischemic cardio-
vascular events in patients who had stable athero-
sclerotic disease or high cardiovascular risk and 
an elevated level of atherogenic lipoproteins de-
spite statin treatment,11,13 with one agent show-
ing benefit only among patients who had a base-
line LDL cholesterol level of at least 100 mg per 
deciliter (2.6 mmol per liter).12
To date, the potential for a PCSK9 antibody 
to reduce cardiovascular risk after an acute coro-
nary syndrome remains undetermined. In the 
ODYSSEY OUTCOMES trial, we tested the hypoth-
esis that treatment with alirocumab, a fully hu-
man monoclonal antibody to PCSK9,13-15 would 
result in a lower risk of recurrent ischemic car-
diovascular events than placebo among patients 
who had an acute coronary syndrome within the 
preceding 1 to 12 months and who have levels 
of atherogenic lipoproteins that exceed specified 
thresholds despite statin therapy at a high-inten-
sity dose or at the maximum tolerated dose.
Me thods
Trial Organization and Oversight
Details of the trial design have been reported 
previously.14 ODYSSEY OUTCOMES was a multi-
center, randomized, double-blind, placebo-con-
trolled trial that was sponsored by Sanofi and 
Regeneron Pharmaceuticals. The protocol and 
statistical analysis plan (available with the full 
text of this article at NEJM.org) were conceived 
by the first three authors, developed in conjunc-
tion with the other members of the executive 
steering committee and sponsors, and approved 
by the responsible regulatory authorities and eth-
ics committees. The sponsors participated in the 
selection of the trial sites, the monitoring of the 
trial, and the supervision of data collection. Duke 
Clinical Research Institute led the blinded adju-
dication of the end points. An independent data 
and safety monitoring committee monitored the 
safety and efficacy data. Analyses were performed 
independently by the academic statistician (the 
third author) in parallel with the sponsors. The 
manuscript was prepared by the first author 
with input from all the authors. The members 
of the executive steering committee made the 
decision to submit the manuscript for publica-
tion and vouch for the completeness and accu-
racy of the data and for the fidelity of the trial 
to the protocol.
Trial Population
Patients were eligible for enrollment in the trial 
if they were 40 years of age or older, had been 
hospitalized with an acute coronary syndrome 
(myocardial infarction or unstable angina) 1 to 
12 months before randomization, and had an 
LDL cholesterol level of at least 70 mg per deci-
liter (1.8 mmol per liter), a non−high-density lipo-
protein (HDL) cholesterol level of at least 100 mg 
per deciliter, or an apolipoprotein B level of at 
least 80 mg per deciliter. All qualifying lipid levels 
were measured after a minimum of 2 weeks of 
stable treatment with atorvastatin at a dose of 40 
to 80 mg once daily, rosuvastatin at a dose of 
20 to 40 mg once daily, or the maximum toler-
ated dose of one of these statins (including no 
statin in the case of documented unacceptable side 
effects). Full trial enrollment criteria are pro-
vided in the Supplementary Appendix, available 
A Quick Take 
is available at 
NEJM.org
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at NEJM.org. All the patients provided written 
informed consent.
Trial Procedures
During a prerandomization run-in phase (de-
scribed in the Supplementary Appendix), patients 
received instruction in injecting themselves (with 
placebo), and lipid levels were verified for patient 
eligibility. Patients who met trial entry criteria 
were randomly assigned, in a 1:1 ratio, to receive 
alirocumab at a dose of 75 mg or matching pla-
cebo; randomization was stratified according 
to country (Table S1 in the Supplementary Ap-
pendix). All doses of alirocumab or placebo were 
administered by subcutaneous injection every 
2 weeks.
The trial-group assignments and lipid levels 
during the trial were concealed from the pa-
tients and investigators. LDL cholesterol levels 
were calculated with the use of the Friedewald 
formula unless the triglyceride level exceeded 
400 mg per deciliter (4.52 mmol per liter) or the 
calculated LDL cholesterol level was found to be 
less than 15 mg per deciliter (0.39 mmol per liter), 
in which case values were determined by beta 
quantification. Among patients assigned to the 
alirocumab group, protocol-specified dose-adjust-
ment algorithms14 were used to target an LDL 
cholesterol level of 25 to 50 mg per deciliter 
(0.6 to 1.3 mmol per liter) and to avoid sustained 
levels below 15 mg per deciliter (details can be 
found in the Additional Information on the 
Methods and Results section and in Figs. S1 and 
S2 in the Supplementary Appendix). Dose adjust-
ments were performed under blinded conditions, 
without either the patient or the investigator be-
ing aware of the adjustment, including substitu-
tion of placebo for alirocumab in the case of 
sustained levels of LDL cholesterol below 15 mg 
per deciliter.
Trial End Points
The primary end point was a composite of death 
from coronary heart disease, nonfatal myocar-
dial infarction, fatal or nonfatal ischemic stroke, 
or unstable angina requiring hospitalization. Pre-
specified main secondary end points were any 
coronary heart disease event (death from coro-
nary heart disease, nonfatal myocardial infarc-
tion, unstable angina requiring hospitalization, 
or an ischemia-driven coronary revascularization 
procedure); major coronary heart disease event 
(death from coronary heart disease or nonfatal 
myocardial infarction); any cardiovascular event 
(death from cardiovascular causes, nonfatal ische-
mic stroke, nonfatal myocardial infarction, un-
stable angina requiring hospitalization, or an 
ischemia-driven coronary revascularization pro-
cedure); a composite of death from any cause, 
nonfatal myocardial infarction, or nonfatal ische-
mic stroke; death from coronary heart disease; 
death from cardiovascular causes; and death from 
any cause. Individual components of the primary 
end point, an ischemia-driven coronary revascu-
larization procedure, and hospitalization for con-
gestive heart failure were additional secondary 
end points. All primary and secondary end points 
were adjudicated by physicians who were un-
aware of the trial-group assignments.
Statistical Analysis
Efficacy was determined by the time to the first 
occurrence of any component of the composite 
primary end point; analyses were performed ac-
cording to the intention-to-treat principle and 
included data from all patients and for all events 
that occurred from the time of randomization to 
the common trial end date. Design assumptions 
included an incidence of the composite primary 
end point of 11.4% at 4 years in the placebo 
group and a median baseline LDL cholesterol 
level of 90 mg per deciliter (2.3 mmol per liter), 
with an anticipated 50% lower LDL cholesterol 
level in the alirocumab group than in the pla-
cebo group, which would result in an expected 
15% lower risk of the primary end point with 
alirocumab than with placebo. It was estimated 
that 1613 composite primary end-point events 
occurring in 18,000 patients over a median fol-
low-up of approximately 3 years would provide 
the trial with 90% power to detect the expected 
difference in risk at a significance level of 0.05. 
In China, 614 patients underwent randomization 
after random assignment of the main trial co-
hort had been completed (as described in the 
Supplementary Appendix). The protocol specified 
that the trial was to continue until at least 1613 
primary end-point events had occurred and all 
patients who could be evaluated were followed 
for at least 2 years (except the patients from 
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China), which would ensure a sufficient obser-
vation time in which to assess safety and ef-
ficacy. Patients from China were not followed 
for 2 years because a lengthy regulatory ap-
proval process delayed their random assignment 
to a trial group until after completion of the 
randomization process for the rest of the trial 
cohort.
LDL cholesterol was evaluated in an inten-
tion-to-treat analysis that included levels mea-
sured after premature discontinuation of the 
trial regimen, levels measured after dose ad-
justments were made under blinded conditions, 
and levels measured after blinded substitution 
of placebo for alirocumab. LDL cholesterol was 
also evaluated in the alirocumab group in an 
on-treatment analysis that excluded levels mea-
sured after premature discontinuation of ali-
rocumab and levels measured after blinded 
substitution of placebo for alirocumab but in-
cluded levels measured after dose adjustments 
of alirocumab between the 75-mg dose and the 
150-mg dose were made under blinded condi-
tions.
Hazard ratios and 95% confidence intervals 
were estimated with the use of a Cox propor-
tional-hazards model, stratified according to 
geographic region; P values were determined 
with the use of stratified log-rank tests. To ad-
just for multiplicity, the results of the main sec-
ondary end points were to be tested in hierar-
chical fashion in the sequence listed above if 
the risk of the composite primary end point was 
found to be significantly lower in the alirocumab 
group than in the placebo group. Two prespeci-
fied interim analyses were performed when 
approximately 50% and 75% of the planned 
primary end-point events for the final analysis 
had occurred; neither led to early termination 
of the trial. To account for the two interim 
analyses, a two-sided P value of less than 
0.0498 was required to declare statistical sig-
nificance for the primary end point at the final 
analysis. Absolute treatment effects in prespeci-
fied subgroups were compared with the use of 
the Gail−Simon test.15 The statistical analysis 
plan and the Supplementary Appendix provide 
details of the descriptive safety analyses and 
analytical methods.
R esult s
Patients, Trial Regimen, and Follow-up
A total of 18,924 patients underwent randomiza-
tion at 1315 sites in 57 countries; 9462 were 
assigned to the alirocumab group and 9462 to 
the placebo group (Fig. S3 in the Supplementary 
Appendix). Except in China, patients underwent 
randomization from November 2012 through 
November 2015. In China, 613 patients under-
went randomization from May 2016 through 
February 2017. At the time of randomization, the 
characteristics of the two trial groups were well 
balanced (Table 1, and Table S2 in the Supple-
mentary Appendix). The qualifying acute coro-
nary syndrome was myocardial infarction in 
83.0% of the patients and unstable angina in 
16.8%. Most of the patients (92.1%) qualified 
with an LDL cholesterol level of 70 mg or more 
per deciliter; a majority of the remaining pa-
tients (7.2%) met only the non−HDL cholesterol 
criterion. The median time from the qualifying 
acute coronary syndrome to randomization was 
2.6 months (interquartile range, 1.7 to 4.3).
Most of the patients received guideline-recom-
mended medications and had undergone coro-
nary revascularization for the index event. At the 
time of randomization, 88.8% of the patients 
were receiving atorvastatin at a dose of 40 mg to 
80 mg daily or were receiving rosuvastatin at a 
dose of 20 mg to 40 mg daily. After 1 year of 
follow-up, 84.7% of the patients in the alirocumab 
group and 86.2% in the placebo group were re-
ceiving such treatment; after 3 years of follow-
up, the percentages were 82.8% in the alirocumab 
group and 86.6% in the placebo group. Infor-
mation on the adjustment of alirocumab doses 
under blinded conditions can be found in the 
Supplementary Appendix.
Patients were followed for a median of 2.8 
years (interquartile range, 2.3 to 3.4); the com-
mon trial end date was November 11, 2017. Pre-
mature discontinuation of the assigned alirocu-
mab or placebo for reasons other than death 
occurred in 1343 patients (14.2%) in the alirocu-
mab group and in 1496 patients (15.8%) in the 
placebo group (Fig. S3 in the Supplementary 
Appendix). Exposure to the intended trial regi-
men as a percentage of the total follow-up time 
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Characteristic
Alirocumab 
(N = 9462)
Placebo 
(N = 9462)
Age — yr 58.5±9.3 58.6±9.4
Female sex — no. (%) 2390 (25.3) 2372 (25.1)
Race — no. (%)†
White 7500 (79.3) 7524 (79.5)
Asian 1251 (13.2) 1247 (13.2)
Black 235 (2.5) 238 (2.5)
Other 475 (5.0) 451 (4.8)
Region of enrollment — no. (%)
Central and Eastern Europe 2719 (28.7) 2718 (28.7)
Western Europe 2084 (22.0) 2091 (22.1)
Canada or United States 1435 (15.2) 1436 (15.2)
Latin America 1293 (13.7) 1295 (13.7)
Asia 1150 (12.2) 1143 (12.1)
Rest of world 781 (8.3) 779 (8.2)
Medical history before index acute coronary syndrome 
 — no. (%)
Hypertension 6205 (65.6) 6044 (63.9)
Diabetes mellitus 2693 (28.5) 2751 (29.1)
Current tobacco smoker 2282 (24.1) 2278 (24.1)
Family history of premature coronary heart disease 3408 (36.0) 3365 (35.6)
Myocardial infarction 1790 (18.9) 1843 (19.5)
Percutaneous coronary intervention 1626 (17.2) 1615 (17.1)
Coronary-artery bypass grafting 521 (5.5) 526 (5.6)
Stroke 306 (3.2) 305 (3.2)
Peripheral artery disease 373 (3.9) 386 (4.1)
Congestive heart failure 1365 (14.4) 1449 (15.3)
Index acute coronary syndrome — no. (%)
ST-segment elevation myocardial infarction 3301 (34.9) 3235 (34.2)
Non−ST-segment elevation myocardial infarction 4574 (48.3) 4601 (48.6)
Unstable angina 1568 (16.6) 1614 (17.1)
Missing data 19 (<0.1) 12 (<0.1)
Percutaneous coronary intervention or coronary-artery bypass  
grafting for index acute coronary syndrome — no. (%)
6798 (71.8) 6878 (72.7)
Median time from index acute coronary syndrome to  
randomization (IQR) — mo
2.6 (1.7–4.4) 2.6 (1.7–4.3)
Body-mass index‡ 28.5±4.9 28.5±4.8
*  Plus–minus values are means ±SD. There were no significant differences between the two groups in demographic  
or baseline characteristics. Additional baseline characteristics are listed in Table S2 in the Supplementary Appendix. 
Percentages may not sum to 100 because of rounding. IQR denotes interquartile range.
†  Race was reported by the patient.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Demographic and Baseline Characteristics of the Patients.*
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was 90.7% in the alirocumab group (including 
time after blinded substitution of placebo for 
alirocumab) and 90.0% in the placebo group. 
Ascertainment of the composite primary end 
point was complete for 99.1% of potential 
 patient-years of follow-up, and ascertainment 
of death was complete for 99.8% of potential 
patient-years of follow-up.
Effect of Trial Regimen on Lipid Levels
At baseline, the mean (±SD) LDL cholesterol level 
was 92±31 mg per deciliter (2.38±0.80 mmol per 
liter). In the alirocumab group, the mean LDL 
cholesterol level (intention-to-treat analysis) at 
4 months, 12 months, and 48 months after ran-
domization was 40 mg per deciliter (1.0 mmol 
per liter), 48 mg per deciliter (1.2 mmol per liter), 
and 66 mg per deciliter (1.7 mmol per liter), re-
spectively; in the placebo group, the mean LDL 
cholesterol level at 4 months, 12 months, and 
48 months after randomization was 93 mg per 
deciliter (2.4 mmol per liter), 96 mg per deciliter 
(2.5 mmol per liter), and 103 mg per deciliter 
(2.7 mmol per liter), respectively (Fig. 1). In the 
on-treatment analysis in the alirocumab group 
(which excluded values measured after discon-
tinuation of alirocumab and after blinded sub-
stitution of placebo for alirocumab), the mean 
LDL cholesterol level at 4 months, 12 months, and 
48 months was 38 mg per deciliter (0.98 mmol 
per liter), 42 mg per deciliter (1.1 mmol per liter), 
and 53 mg per deciliter (1.4 mmol per liter), re-
spectively; these levels were an average of 62.7%, 
61.0%, and 54.7% lower than the respective 
levels in the placebo group. Other lipid measure-
ments are provided in Figure S4 in the Supple-
mentary Appendix.
End Points
A composite primary end-point event occurred 
in 903 patients (9.5%) in the alirocumab group 
and in 1052 patients (11.1%) in the placebo group 
(Table 2); The Kaplan–Meier probability estimate 
at 4 years was 12.5% in the alirocumab group 
and 14.5% in the placebo group (hazard ratio, 
0.85; 95% confidence interval [CI], 0.78 to 0.93; 
P<0.001) (Fig. 2). To prevent the occurrence of 
one primary end-point event, 49 patients (95% CI, 
28 to 164) would need to be treated for 4 years. 
The effect of alirocumab on the relative risk of 
the composite primary end point did not differ 
significantly according to any of the prespecified 
subgroup variables (Fig. S5 in the Supplementary 
Appendix).
As would be expected, the incidence of the 
composite primary end point in the placebo group 
differed across three categories of baseline LDL 
cholesterol levels (<80, 80 to <100, and ≥100 mg 
per deciliter), with the greatest incidence among 
patients in the highest category. Correspond-
ingly, in a nonprespecified analysis, the greatest 
absolute reduction in risk of the composite pri-
mary end point with alirocumab was also shown 
among the patients who had a baseline LDL 
cholesterol level of 100 mg or more per deciliter 
(P<0.001 for the interaction between treatment 
and baseline LDL cholesterol level) (Table S3 and 
Fig. S6 in the Supplementary Appendix). To pre-
vent the occurrence of one primary end-point 
event among patients with a baseline LDL cho-
lesterol level of 100 mg or more per deciliter, 
16 patients (95% CI, 11 to 34) would need to be 
treated for 4 years. Additional analyses related 
to categories of baseline LDL cholesterol are 
Figure 1. LDL Cholesterol Levels during the Trial.
The intention-to-treat analysis (results shown with solid lines) included all 
low-density lipoprotein (LDL) cholesterol values, including levels measured 
after premature discontinuation of the trial regimen, levels measured after 
dose adjustments were made under blinded conditions, and levels measured 
after blinded substitution of placebo for alirocumab. The on-treatment analysis 
(results shown with dashed lines) excluded LDL cholesterol levels measured 
after premature discontinuation of the trial regimen and levels measured 
after blinded substitution of placebo for alirocumab (but included LDL cho-
lesterol levels measured after dose adjustments of alirocumab were made 
under blinded conditions between the 75-mg dose and the 150-mg dose). 
To convert the values for LDL cholesterol to millimoles per liter, multiply  
by 0.02586.
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provided in Table S3 in the Supplementary Ap-
pendix.
Among the main secondary end points, the 
risks of any coronary heart disease event, major 
coronary heart disease events, any cardiovascu-
lar event, and a composite of death from any 
cause, nonfatal myocardial infarction, or nonfa-
tal ischemic stroke were lower among patients 
treated with alirocumab than among those who 
received placebo (Table 2, and Fig. S7 in the 
Supplementary Appendix). A total of 334 pa-
tients (3.5%) in the alirocumab group and 392 
patients (4.1%) in the placebo group died (haz-
ard ratio, 0.85; 95% CI, 0.73 to 0.98).
Safety
The incidence of adverse events and of labora-
tory abnormalities was similar in the alirocumab 
group and the placebo group (Table 3), with the 
exception of local injection-site reaction (3.8% in 
the alirocumab group vs. 2.1% in the placebo 
group, P<0.001). Injection-site reactions (itching, 
redness, or swelling) were usually mild and self-
limited and led to discontinuation of the trial 
regimen in 26 patients in the alirocumab group, 
at a median of 8.3 months after randomization, 
and in 3 patients in the placebo group. Neuro-
cognitive events were reported in 1.5% of the 
patients in the alirocumab group and in 1.8% of 
End Point
Alirocumab 
(N = 9462)
Placebo 
(N = 9462)
Hazard Ratio 
(95% CI) P Value
number of patients (percent)
Primary end point: composite of death from coronary heart 
disease, nonfatal myocardial infarction, fatal or non-
fatal ischemic stroke, or unstable angina requiring 
hospitalization
903 (9.5) 1052 (11.1) 0.85 (0.78–0.93) <0.001
Major secondary end points, in order of hierarchical testing
Any coronary heart disease event* 1199 (12.7) 1349 (14.3) 0.88 (0.81–0.95) 0.001
Major coronary heart disease event† 793 (8.4) 899 (9.5) 0.88 (0.80–0.96) 0.006
Any cardiovascular event‡ 1301 (13.7) 1474 (15.6) 0.87 (0.81–0.94) <0.001
Composite of death from any cause, nonfatal myocardi-
al infarction, or nonfatal ischemic stroke§
973 (10.3) 1126 (11.9) 0.86 (0.79–0.93) <0.001
Death from coronary heart disease 205 (2.2) 222 (2.3) 0.92 (0.76–1.11) 0.38¶
Death from cardiovascular causes 240 (2.5) 271 (2.9) 0.88 (0.74–1.05)
Death from any cause 334 (3.5) 392 (4.1) 0.85 (0.73–0.98)
Other end points‖
Nonfatal myocardial infarction 626 (6.6) 722 (7.6) 0.86 (0.77–0.96)
Fatal or nonfatal ischemic stroke 111 (1.2) 152 (1.6) 0.73 (0.57–0.93)
Unstable angina requiring hospitalization 37 (0.4) 60 (0.6) 0.61 (0.41–0.92)
Ischemia-driven coronary revascularization procedure 731 (7.7) 828 (8.8) 0.88 (0.79–0.97)
Hospitalization for congestive heart failure 176 (1.9) 179 (1.9) 0.98 (0.79–1.20)
*  This end point includes death from coronary heart disease, nonfatal myocardial infarction, unstable angina requiring 
hospitalization, and an ischemia-driven coronary revascularization procedure (definitions can be found in the 
Supplementary Appendix).
†  This end point includes death from coronary heart disease and nonfatal myocardial infarction.
‡  This end point includes any death from cardiovascular causes, nonfatal myocardial infarction, unstable angina requir-
ing hospitalization, an ischemia-driven coronary revascularization procedure, or nonfatal ischemic stroke.
§  The widths of the confidence intervals for the secondary end points were not adjusted for multiplicity, so the intervals 
for the outcomes listed below this outcome should not be used to infer definitive treatment effects.
¶  The hierarchical analysis was stopped after the first nonsignificant P value was observed, in accordance with the hier-
archical testing plan.
‖  The analysis for other end points was not adjusted for multiplicity; therefore, no P values are reported.
Table 2. Composite Primary End Point and Secondary End Points (Intention-to-Treat Population).
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the patients in the placebo group, new-onset 
diabetes (as defined in the Supplementary 
 Appendix) in 9.6% and 10.1%, respectively, and 
hemorrhagic stroke (confirmed by adjudication) 
in less than 0.1% and 0.2%. Neutralizing anti-
drug antibodies were detected in 0.5% of the 
patients in the alirocumab group and in less 
than 0.1% in the placebo group.
Discussion
Among patients who had a previous acute coro-
nary syndrome and in whom lipid levels exceeded 
specified thresholds despite atorvastatin or rosu-
vastatin therapy at a high-intensity dose or at the 
maximum tolerated dose, the risk of a compos-
ite of death from coronary heart disease, non-
fatal myocardial infarction, fatal or nonfatal 
ischemic stroke, or unstable angina requiring 
hospitalization was lower among those who 
were treated with alirocumab than among those 
who received placebo. These benefits were ob-
served in the context of background care that 
included extensive use of evidence-based treat-
ments16-19 as well as the use of a dose-adjustment 
strategy for alirocumab that targeted an LDL 
cholesterol level of 25 to 50 mg per deciliter and 
allowed a level of 15 to 25 mg per deciliter, but 
that avoided sustained levels below 15 mg per 
deciliter.
The absolute benefit of alirocumab with re-
spect to the composite primary end point was 
more pronounced among patients who had a 
baseline LDL cholesterol level of 100 mg or more 
per deciliter than among patients with a lower 
baseline LDL cholesterol level. Similarly, a recent 
meta-analysis showed that intensive lowering of 
LDL cholesterol (primarily with the use of statins) 
resulted in a mortality benefit that was observed 
only among patients with a baseline LDL choles-
terol level of 100 mg or more per deciliter.20
Over a median follow-up period of 2.8 years, 
with more than 8000 patients who were eligible 
to be followed for 3 to 5 years and 6444 patients 
who received the assigned alirocumab or place-
bo for at least 3 years, the incidence of adverse 
events did not differ significantly between the 
two groups, with the exception of local injection-
site reactions. Whether the safety and efficacy of 
alirocumab were influenced by the blinded dose-
adjustment strategy, which was designed to miti-
gate the occurrence of very low levels of LDL 
cholesterol, is unknown. Serious safety concerns 
were also not observed with evolocumab in the 
FOURIER (Further Cardiovascular Outcomes Re-
search with PCSK9 Inhibition in Subjects with 
Elevated Risk) trial,11 which had no lower limit 
for allowable LDL cholesterol levels; however, 
that trial had a shorter median follow-up, and 
very few patients were followed for 3 or more 
years. Neither trial can fully predict longer-term 
safety of treatment with a PCSK9 monoclonal 
antibody.
Lowering of LDL cholesterol levels with alirocu-
mab was sustained but to a lesser extent than 
that reported in previous trials that had a shorter 
duration.9 The increase in LDL cholesterol over 
time in the intention-to-treat analysis reflects 
premature discontinuation of treatment, dose 
reduction or substitution of placebo for alirocu-
mab under blinded conditions, and attenuation 
of the intensity of statin treatment. The last fac-
tor probably also contributed to the rise in LDL 
cholesterol observed in the placebo group, in the 
Figure 2. Cumulative Incidence of the Composite Primary End Point.
Shown is the cumulative incidence of the primary efficacy end point (a com-
posite of death from coronary heart disease, nonfatal myocardial infarction, 
fatal or nonfatal ischemic stroke, or unstable angina requiring hospitaliza-
tion). The Kaplan–Meier rates for the primary end point at 4 years were 
12.5% (95% CI, 11.5 to 13.5) in the alirocumab group and 14.5% (95% CI, 
13.5 to 15.6) in the placebo group. The inset shows the same data on an 
enlarged y axis. The P value was calculated with the use of log-rank tests, 
stratified according to geographic region.
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on-treatment analysis in the alirocumab group, 
and in previous trials involving patients who had 
an acute coronary syndrome.5,21 Antidrug anti-
bodies were detected in few patients and have 
been shown not to influence the lipid-lowering 
efficacy of alirocumab.22
There are noteworthy similarities and dif-
ferences between our trial and the previous 
FOURIER and SPIRE (Studies of PCSK9 Inhibi-
tion and the Reduction of Vascular Events) trials, 
which evaluated the PCSK9 antibodies evolocu-
mab and bococizumab, respectively.11,13 The cur-
rent trial and the FOURIER trial showed similar 
improvements in composite cardiovascular out-
comes with PCSK9 inhibition among patients 
who had a baseline LDL cholesterol level of 70 mg 
or more per deciliter and whose average baseline 
LDL cholesterol level was approximately 90 mg 
per deciliter.10 Both our trial and the SPIRE trial 
showed a more prominent absolute reduction in 
the risk of cardiovascular outcomes with PCSK9 
inhibition among patients who had a baseline 
LDL cholesterol level of 100 mg or more per deci-
liter.12 The current trial showed the efficacy of 
PCSK9 inhibition in high-risk patients who had 
a previous acute coronary syndrome, 89% of whom 
received high-intensity statin therapy, and used a 
blinded dose-adjustment strategy to achieve a 
target range of LDL cholesterol with PCSK9 in-
hibition. The longer duration of follow-up in the 
Variable
Alirocumab 
(N = 9451)
Placebo 
(N = 9443)
Adverse events — no. (%)
Any adverse event 7165 (75.8) 7282 (77.1)
Serious adverse event 2202 (23.3) 2350 (24.9)
Adverse event that led to death 181 (1.9) 222 (2.4)
Adverse event that led to discontinuation of the trial regimen 343 (3.6) 324 (3.4)
Local injection-site reaction 360 (3.8) 203 (2.1)
General allergic reaction 748 (7.9) 736 (7.8)
Diabetes worsening or diabetic complication among patients  
with diabetes at baseline — no./total no. (%)
506/2688 (18.8) 583/2747 (21.2)
New-onset diabetes among patients without diabetes at baseline  
— no./total no. (%)*
648/6763 (9.6) 676/6696 (10.1)
Neurocognitive disorder 143 (1.5) 167 (1.8)
Hepatic disorder 500 (5.3) 534 (5.7)
Cataracts 120 (1.3) 134 (1.4)
Hemorrhagic stroke, adjudicated 9 (<0.1) 16 (0.2)
Laboratory abnormalities at any time — no./total no. (%)
Alanine aminotransferase >3 times upper limit of normal range 212/9369 (2.3) 228/9341 (2.4)
Aspartate aminotransferase >3 times upper limit of normal range 160/9367 (1.7) 166/9338 (1.8)
Total bilirubin >2 times upper limit of normal range 61/9368 (0.7) 78/9341 (0.8)
Creatine kinase >10 times upper limit of normal range 46/9369 (0.5) 48/9338 (0.5)
Antidrug antibodies† 67/9091 (0.7) 32/9097 (0.4)
Neutralizing antidrug antibodies 43/9091 (0.5) 6/9097 (<0.1)
*  New-onset diabetes was defined according to the presence of one or more of the following, with confirmation of the 
 diagnosis by blinded external review by experts in the field of diabetes: an adverse-event report, a new prescription for 
diabetes medication, a glycated hemoglobin level of at least 6.5% on two occasions (and a baseline level of <6.5%), or 
a fasting serum glucose level of at least 126 mg per deciliter (7.0 mmol per liter) on two occasions (and a baseline level 
of <126 mg per deciliter).
†  Antidrug antibodies were defined by the presence of positive responses detected after the start of administration of the 
trial regimen in at least two consecutive postbaseline serum samples, separated by at least a 16-week period.
Table 3. Adverse Events and Laboratory Abnormalities.
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current trial than in previous trials, owing to the 
mandatory minimum 2-year follow-up, facilitated 
the assessment of efficacy and safety. A limitation 
of all three trials is the infrequent use of ezeti-
mibe, for which cardiovascular efficacy was estab-
lished5 after most of the patients had already 
been enrolled and the trials were well under way.
In conclusion, among patients who had a pre-
vious acute coronary syndrome and whose levels 
of atherogenic lipoproteins remained elevated 
despite statin therapy at a high-intensity dose or 
at the maximum tolerated dose, the risk of major 
adverse cardiovascular events was lower among 
those who were treated with alirocumab than 
among those who received placebo.
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